Published in final edited form as:

Int Urol Nephrol. 2015 March ; 47(3): 537–549. doi:10.1007/s11255-015-0909-0.

The Effects of Short-term Vitamin D Supplementation on Glucose Metabolism in Dialysis Patients: A Systematic Review and Meta-Analysis

Harini Sarathy, MD¹, Vedatrayee Pramanik, MD², Jared Kahn³, Matthew K. Abramowitz, MD, MS^{2,4}, Kristen Meier, BA², Preeti Kishore, MD, MS², and Michal L. Melamed, MD, MHS^{2,4}

¹Albert Einstein College of Medicine / Jacobi Medical Center – Department of Internal Medicine

²Albert Einstein College of Medicine Department of Internal Medicine

³Emory University

⁴Albert Einstein College of Medicine, Department of Epidemiology and Population Health

Abstract

Purpose—We tested whether short-term vitamin D supplementation improves insulin resistance in patients with kidney disease, a condition with little intrinsic vitamin D activity.

Methods—PubMed, Embase and CENTRAL were searched for relevant observational studies and randomized clinical trials (RCTs). Random effects models were employed for meta-analysis and effect sizes were summarized as standardized mean difference (SMD) with 95% confidence intervals. Separate analyses were done for RCTs and non-randomized intervention studies (NRIS).

Results—Seventeen studies (5 RCTs and 12 NRIS) were included. The meta-analysis population (n=131) was mostly middle aged (40–50 years), male and non-diabetic, and on hemodialysis. The duration (4–12 weeks) and type of supplementation varied between studies. Among RCTs, compared to placebo, vitamin D supplementation was associated with significant decrease in fasting glucose [SMD -1.13 , (–2.11 to –0.11)] and PTH levels [SMD -1.50 , (–2.95 to –0.04)] but no difference in fasting insulin levels [SMD 1.32 , (–0.15 to 2.79)]. Among NRIS, there was only a significant decrease in PTH levels [SMD -1.68 , (–2.55 to –0.82)] between pre and post-vitamin D treatment levels.

Conclusions—Short term (4–12 weeks) supplementation with vitamin D is associated with lower fasting glucose levels in ESRD with no change in fasting insulin levels. However, the findings from this study are limited by the studies that were used in the meta-analysis, which were mostly small, used multiple different vitamin D compounds and dosing regimens, had large heterogeneity and funnel plots showed there was a dearth of studies with null or negative finding. Therefore, larger randomized clinical trials need to be performed to answer this important clinical question.

Correspondence: Dr. Michal L. Melamed, Division of Nephrology, Department of Medicine, Albert Einstein College of Medicine, 1300 Morris Park Avenue – Ullmann 615, Bronx, NY 10461, (718) 430-3158, (718) 430-8963 (fax), michal.melamed@einstein.yu.edu.

CONFLICT OF INTEREST: The results presented in this paper have not been published previously. None of the authors have any conflicts of interests to declare.

Keywords

dialysis; insulin resistance; meta-analysis; intervention studies; vitamin D

INTRODUCTION

Insulin resistance is described as a reduced biological effect at a given level of serum insulin, and consequently results in hyperinsulinemia to maintain glucose homeostasis.[1] Altered glucose metabolism and insulin resistance are recognized at all stages of chronic kidney disease (CKD) and end-stage renal disease (ESRD).[2, 3] In ESRD, insulin resistance is an independent non-traditional risk factor for cardiovascular mortality and is associated with protein energy wasting and malnutrition.[4] While the exact mechanism remains unclear, a post-receptor defect in the insulin-receptor signaling pathway in skeletal muscle is the likely primary abnormality. Other suggested contributors include adipose tissue dysregulation, inflammation, anemia, metabolic acidosis, uremic toxins, and vitamin D deficiency.[4] Of these, vitamin D requires particular attention because of the kidney's intricate role in vitamin D metabolism, the high prevalence of vitamin D deficiency in CKD, the availability of safe vitamin D and its analogs, and the potential pleiotropic effects of vitamin D which may include CKD-related insulin resistance.[5, 6]

Animal studies have demonstrated improvement in insulin resistance with administration of vitamin D with both increased insulin sensitivity and insulin secretion being affected.[7, 8] The presence of vitamin D receptors on pancreatic beta cells leading to increased intracellular free calcium and thereby insulin secretion, and immune modulation that prevents beta-cell apoptosis are proposed non-classical mechanisms by which vitamin D may improve insulin resistance.[9, 10]

Observational studies and small randomized controlled trials (RCTs) have evaluated the link between vitamin D deficiency and insulin resistance in CKD. These studies have shown both an improvement in glucose metabolism with vitamin D supplementation in ESRD patients[11–13] and no improvement.[14] To clarify this uncertainty, we conducted a systematic review and meta-analysis to obtain a summary understanding and effect size of the impact of vitamin D supplementation (both nutritional and active) on glucose metabolism in dialysis patients. To our knowledge, this is the first meta-analysis of its kind.

SUBJECTS, MATERIALS AND METHODS

Our search strategy was developed with the help of a medical librarian and included a search of PubMed, Embase, and The Cochrane Library CENTRAL Register of Controlled Trials through Aug 31, 2013. Limits were preset to studies conducted in adult humans (18 years and older) and manuscripts published in the English language. The search strategy for all databases was built on MeSH terms for “Vitamin D” AND “Renal Dialysis” AND “Insulin Resistance” OR “Blood Glucose”, with related keywords in the Title /Abstract added to the search.

Two authors (H.S. and V.P.) conducted the search and reviewed all abstracts independently. Manuscripts of potential relevance were retained for a review of the full text. Additional publications were identified from citations of manuscripts, review articles and personal reference lists. Only original manuscripts available in full text were included. Authors were contacted when full texts were needed. Disagreements regarding final inclusion of a study were resolved by consensus or by a third author (M.L.M.).

Data was abstracted in accordance with eligibility criteria set *a priori*. Studies were included if 1) any vitamin D analog or derivative was administered as an intervention, by any route and for any duration, 2) study participants receiving the intervention, were on hemodialysis [HD] or peritoneal dialysis [PD], 3) primary or secondary outcomes involved the measurement of fasting blood glucose or fasting serum insulin as surrogate measures of insulin resistance at baseline and the end of study. We accepted the following study designs: prospective or retrospective, RCTs or non-randomized intervention studies (NRIS) or observational studies. Additional data extraction using standardized abstraction forms included age, sex, weight/BMI, diabetes mellitus status, type of vitamin D, route, dose and duration, type and average duration (months) of dialysis, serum vitamin D, PTH, calcium and phosphate levels as well as randomization, blinding procedures and loss to follow-up.

Statistical analyses

We analyzed the pooled sample of RCTs separately from that of NRIS.[15] Meta-analyses were performed to quantify the change in mean levels of fasting serum glucose, fasting serum insulin and PTH. Most of the NRIS were reported as single group studies with pre- and post-intervention results. Pre-post effect size estimations require knowledge of pre-post correlations (ρ_{12}) that were not reported in the primary studies. Therefore, we analyzed these paired comparisons in sensitivity analyses under assumptions of low ($\rho_{12}=0.2$), moderate ($\rho_{12}=0.5$) and high ($\rho_{12}=0.8$) correlations.

A priori random effects models were employed and standardized mean differences (SMD) with 95% confidence intervals (C.I.) were generated for continuous outcomes using the Dersimonian-Laird model. The SMD is the difference in means between the two groups divided by study-specific standard deviation.[16] The SMD value should be interpreted as the number of standard deviations between the means being compared and is independent of measurement scale.[16] A negative SMD indicates lower levels, whereas a positive SMD indicates higher levels. Cohen's rule of thumb guides interpretation of magnitude of effect size, SMD 0.2: small, SMD 0.5: moderate, SMD>0.8: large.[17]

Heterogeneity across studies was assessed by the Cochran Q statistic and I^2 statistic of measured inconsistency (the percentage of total variance across studies attributable to real differences between studies, than by chance). The magnitude of heterogeneity was categorized as $I^2=25\%$: low, $I^2=50\%$: moderate and $I^2=75\%$: high.[18] Heterogeneity was expected given the wide variation in study design. Strategies to address heterogeneity included use of random-effects modeling that assumes both within-study and between-study variance, and sensitivity analyses excluding 1–2 studies with outlying effect sizes.[19] Funnel plots of effect size against study-level standard error were constructed using the Begg-Mazumdar method to evaluate publication bias. Risk of bias in RCTs was assessed by

the tool provided by Cochrane Back Review Group.[20] Statistical significance was set at two-sided p-value of 0.05 for all analyses. Statistical analyses were performed with Comprehensive Meta-Analysis software version 2.

RESULTS

Figure 1 provides a summary of the search and manuscript retrieval for this review. The initial literature search yielded a total of 223 articles from PubMed and Embase; no new studies were identified from Cochrane CENTRAL. Of note, one paper suggested by personal reference was added to this review. This study was not retrieved by any database search.[14] The final systematic review was performed on 17 studies (Figure 1).[11–14, 21–33]

Study Methodology

Tables 1 and 2 provide a summary of the reviewed studies. Most of the studies included in this review were small. Of the 17 studies, 4 were RCTs.[14, 23, 28, 31] While Mak 1998 did not report a randomization procedure, HD patients were divided into treatment and placebo groups and therefore the study was included as an RCT. The remaining 12 studies were NRIS that also reported a control group of healthy volunteers who served as comparison for demonstrating improvement from baseline values in the HD group after vitamin D treatment.[11, 12, 21, 22, 24–27, 29, 30, 32, 33]

Intervention

Vitamin D formulations varied widely, with the majority of the older studies employing calcitriol (Tables 1 and 2). The duration and dose of Vitamin D was also variable; most studies evaluated vitamin D effects after 4–12 weeks, though this ranged widely from the shortest duration being 2 hrs after intravenous calcitriol, [11, 12] to the longest duration of 24 weeks (6 months).[30] In the NRIS, healthy controls did not receive any intervention. In the RCTs, control groups received dihydrotachysterol, [13] cinacalcet, [14] or placebo.[23, 28, 31]

Demographic Characteristics

Baseline patient characteristics were not well-reported especially in the older NRIS (Table 1). Age diversity was notable but the mean age typically ranged from 40 to 50 years across most studies. While the eligibility criterion only included adult participants, we included two 1992 studies by Mak that specified the age range as 16–22 years. Sex was reported in 7 studies and the majority were male (>50%). Diabetic patients were included in 3 studies.[14, 30, 32] The mean BMI reported in 4 studies was between 20.6 to 34.6 kg/m². [14, 27, 29, 33] Body weight was reported as within 115–120% of ideal weight for height.[11, 12, 24, 25] Ibrahim 2012 studied the impact of cholecalciferol on outcomes in HCV seropositive and seronegative HD patients; for this review, we only used data from HCV seronegative patients for generalizability. Hung 2012 studied a cohort of African-American HD patients; race was not reported in the other studies.

ESRD and Renal dialyses

Ulutas 2013 was the only study done in PD patients.[33] The mean duration of HD, if reported, ranged from 23–47 months. The etiology of ESRD was variable; dietary restrictions were variably reported and typically were for fluids, sodium, potassium and phosphate but not protein. Most studies excluded patients if they had a history of acute or chronic inflammatory conditions, malignancy, were scheduled for or received a renal transplant, had abnormally elevated serum phosphate and calcium levels or took medications affecting liver function or glucose metabolism (except studies that included diabetics). Participants in most studies were on phosphate binders (calcium carbonate or aluminium hydroxide).

Baseline secondary hyperparathyroidism and vitamin D status

The severity of secondary hyperparathyroidism varied across the studies, with baseline mean intact PTH (iPTH) levels ranging from mildly (<400 pg/ml) to severely elevated (>1000 pg/ml) (Tables 3 and 4). Exposure to medications to treat secondary hyperparathyroidism was variable and reported only in the Blair 2008 (cinacalcet) and Hung 2012 (paricalcitol, cinacalcet) studies. Participants in Ulutas 2013 study continued to take 1- α -calciferol for secondary hyperparathyroidism along with the intervention.[33] Other studies had protocols where participants stopped taking vitamin D supplements 2 to 4 weeks prior to the start of the study[11–13, 26, 32]; or were never on vitamin D supplementation.[22, 31] Of note, in the two Mak 1992 studies, participants discontinued oral calcitriol only 3 days prior to study intervention. Baseline vitamin D levels were variably reported (Tables 1 and 2).

Outcomes and Meta-analyses

Short term vitamin D supplementation was associated with decreased fasting serum glucose levels in 3 of 5 RCTs, whereas NRIS demonstrated non-significant decrements; fasting serum insulin outcomes were variable (Tables 3 and 4). Fasting plasma glucose values were fairly normal in most studies, especially in the NRIS (Table 3 and 4). Improved hemoglobin A1C (HbA1C%) values were also observed (Tables 3 and 4).[21, 23, 31, 32] There was greater evidence for improvement of glucose-stimulated insulin secretion based on hyperglycemic clamp testing or glucose tolerance testing (Table 4).[11, 12, 23–26] Similar results were obtained with testing for HOMA-IR, except in the Hung 2012 study (Tables 3 and 4).[14, 31–33] Changes in serum PTH and calcium levels were associated with changes in the primary outcome and also noted independently.

For the meta-analyses, we excluded the Blair 2008 study to avoid bias from the large attrition between the pre- and post-treatment groups (Table 4). Meta-analyses of RCTs showed significantly decreased SMD of post-treatment fasting serum glucose levels [SMD -1.13, 95% C.I. (-2.11 to -0.11); p-value 0.03; heterogeneity: $I^2=83.03$], non-significant increase in fasting serum insulin values [SMD 1.32, 95% C.I. (-0.15 to 2.79); p-value 0.08; heterogeneity: $I^2=87.47$], and significant decrease in PTH levels [SMD -1.50, 95% C.I. (-2.95 to -0.04); p-value 0.04; heterogeneity: $I^2=90.03$] when compared to the placebo group (Table 3, Fig 2A, 2B, 2C). Meta-analyses of pooled NRIS showed significant improvement only in serum PTH levels after vitamin D treatment: fasting serum glucose levels [SMD -0.22, 95% C.I. (-0.51 to 0.07) p-value 0.14; heterogeneity: $I^2=57.80$], fasting

serum insulin levels [SMD 0.45, 95% C.I. (–0.17 to 1.08) p-value 0.16; heterogeneity: $I^2=88.23$] and serum PTH levels [SMD –1.68, 95% C.I. (–2.55 to –0.82) p-value <0.001; heterogeneity: $I^2=88.52$] (Table 4, Fig. 3A, 3B, 3C). Sensitivity analyses at different levels of correlation coefficient (0.2, 0.8) showed similar results (data not shown). In RCTs and NRIS that demonstrated improvement in glucose levels, baseline fasting glucose levels were elevated compared to studies that did not show significant change (Tables 3–4).

Heterogeneity and Sensitivity analyses

The Q values and I^2 values revealed significant heterogeneity as expected (Table 5). There were too few RCTs for sensitivity analyses. For NRIS, after removing 3 studies with outlying effect sizes [12, 26] or with a very different study methodology, [11, 12] or with additional exclusion of the trial of PD patients, [33] heterogeneity was reduced significantly but the summary effect size for serum glucose levels did not change overall (SMD –0.18, 95% C.I. (–0.40 to 0.04) p-value 0.11, Heterogeneity $I^2=13.4$); similar sensitivity analyses did not affect summary effect sizes for serum insulin levels (SMD 0.58, 95% C.I. (–0.21 to 1.38) p-value 0.15; Heterogeneity $I^2=89.00$) or serum PTH levels (SMD –1.53, 95% C.I. (–1.96 to –1.07) p-value <0.001; Heterogeneity $I^2=90.08$).

Risk of Bias Assessment

Most of the RCTs were single-blinded studies with insufficient reporting on randomization, allocation concealment and blinding. There was no selective reporting or loss to follow up in most studies; however methods to deal with attrition were not reported. The Blair 2008 study used as-treated analysis to deal with attrition. Only Hung 2012 had a low risk of bias based on the Cochrane Back Review Group tool.[20] Funnel plots demonstrated a deficiency of studies with null or negative results suggesting a high grade of publication bias.

DISCUSSION

To our knowledge, this is the first systematic review and meta-analysis that evaluates the impact of short term supplementation with vitamin D or its analogs on glucose metabolism in dialysis patients. A large meta-analysis of observational studies had demonstrated a significant reduction in mortality in CKD and ESRD patients who received calcitriol or synthetic vitamin D analogues over 3–5 years.[34] Prior to this, a meta-analysis of RCTs failed to demonstrate a protective effect of vitamin D for mortality, however mortality was not the primary outcome of those primary trials.[35] We found reasonably strong evidence, largely driven by five RCTs, of short-term (up to 12 weeks) vitamin D supplementation associated improvement in glucose metabolism in dialysis patients. Based on Cohen's rule of thumb, the meta-analysis of RCTs demonstrated a significantly large improvement in fasting glucose levels; this effect was not significant among NRIS. A significant decrement in serum PTH was seen in meta-analyses of both RCTs and NRIS. Long-term glycemic outcomes (HbA1C%) also showed an improvement with associated decreases in PTH, though these results could not be meta-analyzed.

Fasting insulin levels are an accepted marker for insulin resistance in normoglycemic subjects; the meta-analysis population was mostly non-diabetic.[1] Review of studies that

tested glucose- responsive insulin sensitivity and insulin secretion revealed an increase in these measures and thereby improvement in insulin resistance after vitamin D supplementation (Table 4).[11, 12, 22, 24–26] Marked variation in testing of HOMA-IR precluded an interpretable quantification of summary effect size.

There was a large degree of heterogeneity in the meta-analysis. However meta-regression to explain these differences was not done due to risk of serious bias given few RCTs.[16, 36] Unexplained heterogeneity could be secondary to residual confounding and/or bias, especially in NRIS.[15]

Paricalcitol, a vitamin D analog was found to have a null impact in the Hung 2012 study. It also had a null effect on short term glucose metabolism among non-diabetic, non-dialysis stage 3–4 CKD patients (deBoer et al, 8 weeks) and on left ventricular mass (PRIMO Trial, 48 weeks).[37, 38] Paricalcitol has been found to suppress 25(OH)D levels, raising the possibility that vitamin D analogs may function differently from compounds that raise 25(OH)D levels.[37] As non-classical effects of vitamin D are likely dependent on circulating levels of 25(OH)D and local levels of extra-renal 1- α -hydroxylase enzyme, further clinical trials are needed that study compounds which raise 25(OH)D levels.[5]

Autier et al examined the association of vitamin D with various health outcomes in an extensive meta-analyses of prospective cohort studies and RCTs but did not find compelling evidence of a beneficial effect of vitamin D supplementation on glucose metabolism outcomes.[39] However, these trials involved non-ESRD patients who had higher baseline levels of vitamin D and physiological renal activity enabling vitamin D activation, a significant difference from patients in our studies. Moreover, an interesting observation in our meta-analysis was that vitamin D associated improvement in fasting glucose levels was seen in participants with impaired glucose tolerance at baseline, a common feature of the ESRD population. Also, fasting insulin levels were notably lower or borderline in most of these HD study populations, than would be expected for insulin resistance in the general population (variably defined to be >12 mU/ml to >17 mU/ml).[40] This could be explained by the fact that insulin is removed by HD, again attesting to the special status of this population.[41]

It remains uncertain if correction of hyperparathyroidism is a mediator for vitamin D associated changes in glucose metabolism or if these changes in PTH levels are merely expected side-effects of supplementation. In the study demonstrating protective effect of vitamin D supplementation on mortality in ESRD patients, meta-regression demonstrated greater risk reduction among those with higher baseline PTH levels.[34] There is evidence to suggest an independent association of PTH and insulin resistance.[42] It is beyond the scope of this meta-analysis to establish the mechanisms of the observed differences.

Our study has its limitations. Firstly, outcomes varied by definition and measurement, only a few studies measured outcomes of interest such as HOMA-IR.[14, 31, 32] Hyperglycemia and glucose intolerance only manifest at later stages of insulin resistance when it cannot be overcome by insulin secretion.[4] Hyperinsulinemic euglycemic clamp studies and intravenous glucose tolerance tests are cumbersome and were infrequently conducted,

though they are the gold standard test for insulin resistance.[11–14] Secondly, the design and quality of studies varied extensively. Despite this, RCTs demonstrated a significant summary effect of vitamin D supplementation on fasting serum glucose levels. Thirdly, most of the studies had small sample sizes and were focused on short-term outcomes (4–12 weeks) that are not long enough to adequately study relevant clinical outcomes.

In conclusion, improved fasting glucose levels are observed after short-term vitamin D supplementation in dialysis patients with associated decreases in serum PTH levels. However, well-designed larger clinical trials are needed to focus on long term clinical outcomes of insulin resistance and related cardiovascular outcomes in ESRD.

Acknowledgments

Dr. Melamed and Dr. Abramowitz are supported by grant DK 087783 from the National Institute of Diabetes, Digestive and Kidney Diseases and by Gottschalk Awards from the American Society of Nephrology (ASN Foundation for Kidney Research). Dr. Melamed was also supported by grant DK 078774.

References

1. Singh B, Saxena A. Surrogate markers of insulin resistance: A review. *World J Diabetes*. 2010; 1(2):36–47. [PubMed: 21537426]
2. de Boer IH. Vitamin D and glucose metabolism in chronic kidney disease. *Curr Opin Nephrol Hypertens*. 2008; 17(6):566–572. [PubMed: 18941348]
3. Fliser D, Pacini G, Engelleiter R, Kautzky-Willer A, Prager R, Franek E, Ritz E. Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. *Kidney international*. 1998; 53(5):1343–1347. [PubMed: 9573550]
4. Hung AM, Ikizler TA. Factors determining insulin resistance in chronic hemodialysis patients. *Contributions to nephrology*. 2011; 171:127–134. [PubMed: 21625101]
5. Jones G. Expanding role for vitamin D in chronic kidney disease: importance of blood 25-OH-D levels and extra-renal 1 α -hydroxylase in the classical and nonclassical actions of 1 α ,25-dihydroxyvitamin D(3). *Seminars in dialysis*. 2007; 20(4):316–324. [PubMed: 17635821]
6. Holick MF. Vitamin D deficiency. *The New England journal of medicine*. 2007; 357(3):266–281. [PubMed: 17634462]
7. Maestro B, Campion J, Davila N, Calle C. Stimulation by 1,25-dihydroxyvitamin D3 of insulin receptor expression and insulin responsiveness for glucose transport in U-937 human promonocytic cells. *Endocrine journal*. 2000; 47(4):383–391. [PubMed: 11075718]
8. Norman AW, Frankel JB, Heldt AM, Grodsky GM. Vitamin D deficiency inhibits pancreatic secretion of insulin. *Science*. 1980; 209(4458):823–825. [PubMed: 6250216]
9. Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. *American journal of physiology Renal physiology*. 2005; 289(1):F8–28. [PubMed: 15951480]
10. Sergeev IN, Rhoten WB. 1,25-Dihydroxyvitamin D3 evokes oscillations of intracellular calcium in a pancreatic beta-cell line. *Endocrinology*. 1995; 136(7):2852–2861. [PubMed: 7789310]
11. Mak RH. Intravenous 1,25 dihydroxycholecalciferol corrects glucose intolerance in hemodialysis patients. *Kidney international*. 1992; 41(4):1049–1054. [PubMed: 1513086]
12. Mak RH. Amelioration of hypertension and insulin resistance by 1,25-dihydroxycholecalciferol in hemodialysis patients. *Pediatr Nephrol*. 1992; 6(4):345–348. [PubMed: 1498003]
13. Mak RH. 1,25-Dihydroxyvitamin D3 corrects insulin and lipid abnormalities in uremia. *Kidney international*. 1998; 53(5):1353–1357. [PubMed: 9573552]
14. Hung AM, Sundell MB, Plotnikova NE, Bian A, Shintani A, Ellis CD, Siew ED, Ikizler TA. A pilot study of active vitamin D administration and insulin resistance in African American patients undergoing chronic hemodialysis. *Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation*. 2013; 23(3):185–193.

15. Reeves, BCDJ.; Higgins, JPT.; Wells, GA. Chapter 13: Including non-randomized studies. In: Higgins, JPT.; Green, S., editors. *Cochrane Handbook for Systematic Reviews of Interventions* Version 501 [updated September 2008]. Vol. 2008. The Cochrane Collaboration; 2008. Available from www.cochrane-handbook.org
16. Higgins, JPTGS. *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 [updated March 2011]. Vol. 2011. The Cochrane Collaboration; 2011. Available from www.cochrane-handbook.org
17. Cohen, J. *Statistical power analysis for the behavioral sciences*. 2. Hillsdale, NJ: Erlbaum; 1988.
18. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *Bmj*. 2003; 327(7414):557–560. [PubMed: 12958120]
19. Deeks, JJHJ.; Altman, DG.; Higgins, JPTGS., editors. *Cochrane Handbook for Systematic Reviews of Interventions* Version 501 [updated September 2008]. Vol. 2008. The Cochrane Collaboration; 2008. Chapter 9: Analysing data and undertaking meta-analyses. Available from www.cochrane-handbook.org
20. Furlan AD, Pennick V, Bombardier C, van Tulder M. Editorial Board CBRG. 2009 updated method guidelines for systematic reviews in the Cochrane Back Review Group. *Spine*. 2009; 34(18):1929–1941. [PubMed: 19680101]
21. Lind L, Lithell H, Wengle B, Wrege U, Ljunghall S. A pilot study of metabolic effects of intravenously given alpha-calcidol in patients with chronic renal failure. *Scand J Urol Nephrol*. 1988; 22(3):219–222. [PubMed: 3187441]
22. Quesada JM, Martin-Malo A, Santiago J, Hervas F, Martinez ME, Castillo D, Barrio V, Aljama P. Effect of calcitriol on insulin secretion in uraemia. *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*. 1990; 5(12):1013–1017.
23. Turk S, Yeksan M, Tamer N, Gurbilek M, Erdogan Y, Erkul I. Effect of 1,25 (OH)2D3 treatment on glucose intolerance in uraemia. *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*. 1992; 7(12): 1207–1212.
24. Lin SH, Lin YF, Lu KC, Diang LK, Chyr SH, Liao WK, Shieh SD. Effects of intravenous calcitriol on lipid profiles and glucose tolerance in uraemic patients with secondary hyperparathyroidism. *Clin Sci (Lond)*. 1994; 87(5):533–538. [PubMed: 7874841]
25. Lu KC, Shieh SD, Lin SH, Chyr SH, Lin YF, Diang LK, Li BL, Sheu WH, Ding YA. Hyperparathyroidism, glucose tolerance and platelet intracellular free calcium in chronic renal failure. *Q J Med*. 1994; 87(6):359–365. [PubMed: 8041868]
26. Kautzky-Willer A, Pacini G, Barnas U, Ludvik B, Streli C, Graf H, Prager R. Intravenous calcitriol normalizes insulin sensitivity in uremic patients. *Kidney international*. 1995; 47(1):200–206. [PubMed: 7731147]
27. Gunal AI, Celiker H, Celebi H, Ustundag B, Gunal SY. Intravenous alfacalcidol improves insulin resistance in hemodialysis patients. *Clinical nephrology*. 1997; 48(2):109–113. [PubMed: 9285148]
28. Khajehdehi P, Taheri S. Effect of oral calcitriol pulse therapy on the lipid, calcium, and glucose homeostasis of hemodialysis-patients: its safety in a combination with oral calcium carbonate. *Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation*. 2003; 13(2):78–83.
29. Strozeki P, Kretowicz M, Odrowaz-Sypniewska G, Manitus J. The influence of intravenous 1,25(OH)2D3 therapy on glucose metabolism in hemodialyzed patients with secondary hyperparathyroidism. *Ren Fail*. 2004; 26(4):345–348. [PubMed: 15462099]
30. Blair D, Byham-Gray L, Lewis E, McCaffrey S. Prevalence of vitamin D [25(OH)D] deficiency and effects of supplementation with ergocalciferol (vitamin D2) in stage 5 chronic kidney disease patients. *Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation*. 2008; 18(4):375–382.
31. Bonakdaran S, Ayatollahi H, Mojahedi MJ, Sharifipour F, Shakeri M. Impact of treatment with oral calcitriol on glucose intolerance and dyslipidemia(s) in hemodialysis patients. *Saudi J Kidney Dis Transpl*. 2008; 19(6):942–947. [PubMed: 18974581]

32. Ibrahim MA, Sany D, El Shahawy Y, Awdallah A. Effect of activated vitamin D on glucoparameters in HCV seropositive and seronegative patients on chronic hemodialysis. *Ren Fail.* 2012; 34(10):1188–1194. [PubMed: 22871095]
33. Ulutas O, Taskapan H, Taskapan MC, Temel I. Vitamin D deficiency, insulin resistance, serum adipokine, and leptin levels in peritoneal dialysis patients. *International Urology and Nephrology.* 2013; 45:879–884. [PubMed: 23065434]
34. Duranton F, Rodriguez-Ortiz ME, Duny Y, Rodriguez M, Daures JP, Argiles A. Vitamin D treatment and mortality in chronic kidney disease: a systematic review and meta-analysis. *American journal of nephrology.* 2013; 37(3):239–248. [PubMed: 23467111]
35. Palmer SC, Gregor DO, Makaskill P, Craig JC, Elder GJ, Strippoli GFM. Meta-analysis: Vitamin D Compounds in Chronic Kidney Disease. *Annals of Internal Medicine.* 2007; 147(12):840–853. [PubMed: 18087055]
36. Thompson SG, Higgins JPT. How should meta-regression analyses be undertaken and interpreted? *Statistics in Medicine.* 2002; 21(11):1559–1574. [PubMed: 12111920]
37. De Boer IH, Sachs M, Hoofnagle AN, Utzschneider KM, Kahn SE, Kestenbaum B, Himmelfarb J. Paricalcitol does not improve glucose metabolism in patients with stage 3–4 chronic kidney disease. *Kidney international.* 2013; 83(2):323–330. [PubMed: 22913981]
38. Thadhani R, Appelbaum E, Pritchett Y, Chang Y, Wenger J, Tamez H, Bhan I, Agarwal R, Zoccali C, Wanner C, et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. *JAMA : the journal of the American Medical Association.* 2012; 307(7):674–684.
39. Autier P, Boniol M, Pizot C, Mullie P. Vitamin D status and ill health: a systematic review. *The Lancet Diabetes & Endocrinology.*
40. Ascaso JF, Pardo S, Real JT, Lorente RI, Priego A, Carmena R. Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism. *Diabetes care.* 2003; 26(12):3320–3325. [PubMed: 14633821]
41. Abe M. Plasma insulin is removed by hemodialysis: evaluation of the relation between plasma insulin and glucose by using a dialysate with or without glucose. *Ther Apher Dial.* 2007; 11(4)
42. Alemzadeh R, Kichler J. Parathyroid hormone is associated with biomarkers of insulin resistance and inflammation, independent of vitamin D status, in obese adolescents. *Metabolic syndrome and related disorders.* 2012; 10(6):422–429. [PubMed: 22849753]

Figure 1.
Flow diagram of studies identified for systematic review and meta-analysis.

RCT: Serum Glucose

Random Effects Model: I-squared: 83.03

Fig 2a

RCT: Serum Insulin

Random Effects Model: I-squared: 87.47

Fig 2b

RCT: Serum PTH

Random Effects Model: I-squared: 90.04

Fig 2c

Fig. 2.

Fig 2a: Forest plot of pooled randomized controlled trials to evaluate the summary effect (Standardized Mean Difference) of vitamin D intervention group compared to placebo group on fasting serum glucose.

Fig 2b: Forest plot of pooled randomized controlled trials to evaluate the summary effect (Standardized Mean Difference) of the vitamin D intervention group compared to the placebo group on fasting serum insulin.

Fig 2c: Forest plot of pooled randomized controlled trials to evaluate the summary effect (Standardized Mean Difference) of the vitamin D intervention group compared to the placebo group on serum PTH levels.

NRIS: Serum Glucose

Random Effects Model: I-squared: 57.79

Fig 3a

NRIS: Serum Insulin

Random Effects Model: I-squared: 88.32

Fig 3b

NRIS: Serum PTH

Random Effects Model: I-squared: 88.51

Fig 3c

Fig. 3.

Fig 3a: Forest plot of pooled Non-Randomized Intervention Studies (NRIS) to evaluate the summary effect (Standardized Mean Difference) comparing pre- and post-vitamin D fasting serum glucose levels.

Fig 3b: Forest plot of pooled Non-Randomized Intervention Studies (NRIS) to evaluate the summary effect (Standardized Mean Difference) comparing pre- and post-vitamin D fasting serum insulin levels.

Fig 3c: Forest plot of pooled Non-Randomized Intervention Studies (NRIS) to evaluate the summary effect (Standardized Mean Difference) comparing pre- and post-vitamin D serum PTH levels.

Table 1

Descriptive characteristics of randomized controlled trials (RCTs) of vitamin D supplementation with insulin resistance as an outcome.

Author name, Year of publication	Study Design	Vit D formulation & Placebo used, route, dose, duration.	Number of subjects in intervention & placebo/control groups respectively	Mean Age (yr)	Diabetic patients	Intervention group: Mean Baseline Vit D levels (SD)
Mak 1998	Prospective, single center, unclear blinding, unclear randomization placebo-controlled trial	IV Calcitriol 1.5–2.5mcg 3 times weekly for 4 weeks vs. Oral Dihydroxycholesterol (DHT) 0.5–1mg daily for 4 weeks	8 HD subjects each in intervention & placebo groups + 7 healthy controls	18	No	1,25(OH)2D 3 (pg/ml): 12 (3.0)
Turk 1992	Prospective, single center, unclear blinding, randomized placebo-controlled trial	Oral calcitriol 0.5mcg/day x 8 weeks vs. Placebo x 8 weeks	16 HD subjects & 15 HD subjects in control group	39.2	No	1,25(OH)2D 3 (pg/ml): 17.41 (6.03)
Khajehdehi 2003	Prospective, single-center, unclear blinding, randomized, placebo-controlled crossover study	Oral pulse calcitriol (0.03mcg/body weight) i.e. 1.5–2.25mcg 2 times weekly at the end of HD session x 12 weeks vs. Placebo x 12 weeks	24 HD subjects each in intervention and placebo group	53.2	No	-
Bonakdaran 2008	Prospective, single center, single blinded, randomized placebo-controlled clinical trial	Oral Calcitriol 0.5 mcg / day x 8 weeks vs. placebo x 8 weeks	13 HD subjects and 14 HD subjects in placebo group	48	No	-
Hung 2012	Prospective, single-center, double-blinded, randomized, placebo-controlled parallel-design study	Paricalcitol adjusted to goal of maintaining iPTH level within 10% variation of baseline value (after an 8 week withdrawal period) vs. control group: cinacalcet x 8 weeks	5 HD subjects each in intervention and placebo group	47	Yes ; A1C<10 %	25(OH)D (ng/ml): 19.8 (10.0)

Table 2

Descriptive characteristics of non-randomized intervention studies (NRIS) of vitamin D supplementation with insulin resistance as an outcome.

Author, publication year	Vit D formulation & Placebo used, route, dose, duration.	Number of subjects in intervention & placebo/ control groups respectively	Mean Age (yr)	Diabetic patients	Intervention group: Mean Baseline Vit D levels (SD)
1-ALPHA-CALCIDOL					
Lind 1988	IV 1-Alpha-Calcidol 0.5–3.0mcg 3 times a week after HD sessions for 12 weeks	7 HD subjects & 7 healthy controls	-	Unclear	-
Gunal 1997	IV 1-Alpha-Calcidol 2mcg 2–3 times a week after HD sessions for 4 weeks	14 HD subjects & 10 healthy controls	44.57	No	-
Ibrahim 2012	Oral 1-Alpha-Calcidol 0.25–0.5mcg per day (adjusted according to levels of serum Calcium, Phos, Ca x Phos product and PTH) for 12 weeks	20 HCV seronegative HD subjects	-	Yes	25(OH)D (ng/ml): 24.42 (6.28)
INTRAVENOUS CALCITRIOL					
Mak 1992, Pediatr Nep	IV Calcitriol 2mcg/m ² after discontinuing oral Vit D supplementation 3 days prior to study	7 HD subjects & 7 healthy controls	-	No	-
Mak 1992, Kidney Intl	IV Calcitriol 2mcg/m ² after discontinuing oral Vit D supplementation 3 days prior to study	11 HD subjects & 11 healthy controls	-	No	-
Lin 1994	IV Calcitriol 1mcg 3 times weekly after HD sessions for 8 weeks	15 HD subjects & 15 healthy controls	47.7	No	1,25(OH)2D3 (pg/ml): 7.79 (0.33)**
Lu 1994	IV Calcitriol 1 mcg 3 times weekly at end of HD sessions for 4 weeks	18 HD subjects & 12 healthy controls	48	No	1,25(OH)2D3 (pg/ml): 8.54 (0.36)
Kautzky-Willer 1995	IV Calcitriol 1mcg 3 times weekly after HD sessions for 12 weeks	10 HD subjects & 10 healthy controls	40.1	No	1,25(OH)2D3 (pg/ml): 17.1 (7.1)
Strozecki 2008	IV Calcitriol 1–2mcg 3 times weekly at end of HD sessions (average dose 4.5/week) for 12 weeks	8 HD subjects & 14 healthy controls	49.5	No	-
ORAL CALCITRIOL					
Quesada 1990	Oral Calcitriol 0.5mcg daily for 2 weeks	9 HD subjects & 9 healthy controls	-	No	1,25(OH)2D3 (pg/ml): 11 (0.7)
MISCELLANEOUS VITAMIN D FORMULATIONS					
Blair 2008	Oral Ergocalciferol, 50,000 IU/week for 24 weeks	318 HD subjects in intervention group, No controls.	61.9	Yes	25(OH)D (ng/ml): 18.35 (8.99)
Ulusas 2013	Oral cholecalciferol 50,000 IU/week for 4–8 weeks. 18/19 patients received 1-alpha calciferol for PTH control	19 PD subjects in intervention group, No controls.	47.2	No	25(OH)D (ng/ml): 10 (4.7)

Table 3

Baseline and post-treatment glycemic parameters for randomized controlled trials (RCTs). All values reported as baseline (standard deviation), post-treatment (standard deviation), p-value.

Author, publication year	Intervention group: Fasting Serum Glucose (mg/dl)	Intervention group: Fasting Serum Insulin (μ U/ml)	Intervention group: Serum intact PTH (pg/ml)	Intervention group: Serum Calcium (mg/dl)	Intervention group: Serum Phosphate (mg/dl)	Final outcome
Mak 1998	103 (5), 88 (4), <0.05	7 (1), 12 (1), <0.05	798.0 (90.0), 763.0 (101.0), >0.05[‡]	9.1 (0.2), 9.5 (0.2), >0.05[‡]	6.3 (0.3), 6.6 (0.3), >0.05[*]	$\uparrow$ S Insulin, $\downarrow$ S.Glucose.
Turk 1992	107.1 (3.4), 94.6 (2.2), <0.01	7.8 (0.7), 11.6 (1.0), <0.01	204.8 (30.1), 116.7 (17.4), <0.001	7.8 (0.2), 9.2 (0.2), <0.01	-	$\uparrow$ Basal Insulin $\downarrow$ Fasting Glucose (similar increase in OGTT values of insulin and glucose - not shown here) $\downarrow$ PTH $\uparrow$ S.Calcium
Khajehdehi 2003	107.8 (11.1), 95.5 (5.1), <0.001	-	397.8 (114.5), 160.4 (96.7), <0.03	8.95 (0.47), 9.70 (0.62), <0.03	5.07 (0.93), 5.00 (0.82), >0.05[*]	$\downarrow$ Fasting glucose, $\downarrow$ PTH. $\uparrow$ S.Calcium
Bonakdaran 2008	105.0 (52.0), 85.3 (22.3), 0.07	10.4 (4.1), 9.3 (3.8), 0.31	405.0 (221.6), 271.7 (226.1), 0.05	8.9 (0.4), 9.4 (0.6), 0.01	5.3 (1.1), 5.1 (1.5), 0.77	$\downarrow$ HOMA-IR $\downarrow$ HbA1C% Non-significant increment in beta-cell insulin secretion (not shown) Non-significant decrease in PTH
Hung 2012 ^{**}	117.8 (17.9), 118.8 (9.5), >0.05[*]	21.4 (9.6), 25.7 (22.5), >0.05[*]	605.4 (306.2), 531.8 (361.9), >0.05[*]	7.9 (0.7), 9.6 (1.3), >0.05[*]	4.9 (1.5), 6.2 (1.2), >0.05[*]	No significant change in glucose, insulin PTH or HOMA-IR values.

* Non-significant p-values not specified in the original manuscript

** Baseline is considered to be at 8 weeks after paricalcitol washout and just prior to randomization. Post-treatment values are at 16 weeks.

OGTT: Oral Glucose Tolerance Test, IVGTT: Intravenous Glucose Tolerance Test

Table 4

Baseline and post-treatment glycemic parameters for the non-randomized intervention studies. All values reported as baseline (standard deviation), post-treatment (standard deviation), p-value.

Author name, publication year	Fasting Serum Glucose (mg/dl)	Fasting Serum Insulin (μU/ml)	Serum intact PTH (pg/ml)	Serum Calcium (mg/dl)	Serum Phosphate (mg/dl)	Final outcome
Lind 1988	126.0 (64.8), 111.6 (66.6), >0.05*	12.0 (7.7), 16.8 (14.1), >0.05*	-	-	-	↓ HbA1C
Gunal 1997	88.7 (4.0), 88.1 (3.6), >0.05*	30.5 (7.3), 28.7 (9.2), >0.05*	1085.0 (822.1), 772.1 (620.1), <0.004	8.6 (1.0), 9.1 (0.6), <0.05	6.4 (3.2), 7.4 (1.9), <0.05	↓ PTH and ↑ S Calcium
Ibrahim 2012	112.9 (44.5), 90.6 (24.8), 0.001	10.2 (3.7), 22.6 (6.4), 0.001	82 (52–850), 195 (20–1333), 0.14 (Median (IQR))	7.9 (0.5), 8.4 (0.5), 0.002	5.2 (0.8), 5.2 (0.7), 0.81	↓ HbA1c, ↓ basal Glucose, ↑ Fasting Insulin values, ↑ HOMA-IR after treatment; ↑ S.Calcium.
Mak 1992, PedNephrol	98 (1.8), 95 (1.5), >0.05*	11.2 (2.2), 10.9 (1.6), >0.05*	305.0 (95.1), 294.0 (85.7), >0.05*	8.4 (0.4), 8.9 (0.3), >0.05*	7.2 (0.9), 7.1 (1.0), >0.05*	Acute IV Calcitriol significantly improved insulin sensitivity in hyperglycemic clamp conditions in uremic patients (not shown)
Mak 1992, Kidney Intl	89.0 (2.2), 86.8 (3.4), >0.05*	12.4 (2.8), 16.0 (2.1), >0.05*	246.0 (107.6), 225.0 (99.1), >0.05*	9.3 (0.4), 9.7 (0.4), >0.05*	7.3 (0.9), 7.1 (1.0), >0.05*	Acute IV Calcitriol increased insulin secretion during hyperglycemic clamp conditions and also corrected glucose intolerance in IVGTT.
Lin 1994	83.5 (9.5)*, 85.3 (7.6), >0.05*	17.8 (2.6)*, 19.9 (2.7), >0.05*	476.6 (48.3), 191.4 (30.2), <0.001	9.1 (0.2), 9.9 (0.3), <0.001	4.4 (0.2), 4.9 (0.2), >0.05*	OGTT: Insulinogenic index and AUC for insulin increased after calcitriol (not shown); ↓ PTH ↓ S.Calcium.
Lu 1994	86.5 (9.5), 85.0 (7.0), >0.05*	17.8 (2.7), 19.6 (2.5), >0.05*	476.8 (53.2), 208.2 (42.5), <0.001	9.1 (0.3), 9.9 (0.3), <0.001	4.6 (0.2), 5.2 (0.2), >0.05*	OGTT: AUC for glucose decreased, whereas insulinogenic index and AUC for insulin increased after calcitriol (not shown); ↓ PTH ↓ S.Calcium.
Kautzky-Willer 1995	77.4 (2.7)** , 79.2 (1.98), >0.05*	13.0 (1.7)** , 10.3(1.0), <0.05	432.0 (60.0)** , 237.0 (30.0), <0.05	8.7 (0.1)** , 9.0 (0.1), >0.05*	7.2 (0.8)** , 7.8 (0.7), >0.05*	↓ in basal insulin secretion. ↓ PTH. No difference in glucose effectiveness; Marked elevated insulin and C-peptide at basal and dynamic conditions. Increase in hepatic insulin extraction after calcitriol (not shown).
Strozecki 2008	86.3 (14.9), 85.4 (14.8), 0.79	9.5 (4.2), 9.1 (4.8), 0.57	1088.6 (472.2), 506.1 (646.3), <0.02	9.0 (1.0)* , 10.4 (0.6), <0.01	7.8 (0.8)* , 8.6 (1.2), >0.05*	↓ HbA1C ↓ PTH, ↑ S.Calcium

Author name, publication year	Fasting Serum Glucose (mg/dl)	Fasting Serum Insulin (µU/ml)	Serum intact PTH (pg/ml)	Serum Calcium (mg/dl)	Serum Phosphate (mg/dl)	Final outcome
Quesada 1990	-	7.5 (3.1), 34.6 (3.6), <0.001	182.0 (73.0) *, 88.3 (9.4), <0.03	8.6 (0.2), 8.8 (0.2), >0.05*	5.7 (0.4), 5.8 (0.4), >0.05*	↑ Basal Insulin secretion and post-OGTT insulin secretion, ↓ PTH
Blair 2008	-	-	451.4 (434.2), 422.7 (414.1), >0.05* (Npre-rx=303; Npost-rx=150)	8.7 (0.8), 8.5 (0.9), 0.002 (Npre-rx=318; Npost-rx=165)	5.3 (1.6), 5.1 (1.4), >0.05* (Npre-rx=318; Npost-rx=165)	↓ HbA1C
Uluas 2013	95.4 (11.2), 93.1 (12.2), 0.67	17.6 (11.2), 11.9 (7.8), 0.02	551.9 (276.6), 434.0 (273.4), 0.03	9.4 (0.9), 9.2 (0.6), 0.10	4.7 (0.9), 4.9 (1.4), 0.78	↓ HOMA-IR, ↓ PTH IR decreased with additional Vit D replacement in PD patients who were already receiving active vit D repletion.

* Non-significant p-values not reported in original manuscript

** Units were reported alternately in original manuscript and have been converted here.

OGTT: Oral Glucose Tolerance Test, IVGTT: Intravenous Glucose Tolerance Test

Npre-rx: Number in pre-treatment group; Npost-rx: Number in post-treatment group

Summary Effect Size (Standardized mean difference (SMD)) from Meta-analysis of Randomized Controlled Trials (comparing intervention group to placebo group) and Non-Randomized Intervention Studies (comparing pre- and post- values).

Table 5

Parameter	SMD	95% C.I.	p-value	Heterogeneity: I ²	Q-statistic	p-value
RANDOMIZED CONTROLLED TRIALS: Correlation Coefficient 0.5						
Fasting Serum Glucose	-1.13	-2.1 to -0.11	0.03	83.03	23.57	<0.001
Fasting Serum Insulin	1.32	-0.15 to 2.79	0.08	87.47	23.94	<0.001
Serum intact PTH	-1.50	-2.95 to -0.04	0.04	90.03	40.15	<0.001
NON-RANDOMIZED INTERVENTION STUDIES: Correlation Coefficient 0.5						
Fasting Serum Glucose	-0.22	-0.51 to 0.07	0.14	57.80	21.32	0.01
Fasting Serum Insulin	0.45	-0.17 to 1.08	0.16	88.23	85.00	<0.001
Serum intact PTH	-1.68	-2.55 to -0.82	<0.001	88.52	69.67	<0.001